Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 06, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The material change reported is an increase in the notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan. This adjustment resulted from a re-valuation of the cash element of the notional investment held in GSK Ordinary Share ADRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The transaction was executed at a price of $44.92 per ADR on May 01, 2008, and notified on May 06, 2008, in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing reports a re-valuation of the US Retirement Savings Plan held in GSK Ordinary Share ADRs.
- The transaction price was $44.92 per ADR.
- Notable increases in notional allocations were recorded for Dr. R G Greig (142 shares) and Mr. E J Gray (17 shares).
- This document does not contain financial statements or operational results for the company.